<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="71214"><DrugName>meloxicam (SoluMatrix/arthritis), iCeutica</DrugName><DrugNamesKey><Name id="43074591">Vivlodex</Name><Name id="42755707">meloxicam</Name></DrugNamesKey><DrugSynonyms><Name><Value>meloxicam</Value><Types><Type>USAN</Type><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>meloxicam (SoluMatrix/arthritis), iCeutica</Value></Name><Name><Value>meloxicam nanoformulation capsules (arthritis), iCeutica</Value></Name><Name><Value>Vivlodex</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>IP-045</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>71125-38-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1021736">iCeutica Inc</CompanyOriginator><CompaniesPrimary><Company id="1021736">iCeutica Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1021736" type="Company"><TargetEntity id="4296014303" type="organizationId">iCeutica Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="245" type="ciIndication"><TargetEntity id="10031161" type="MEDDRA"/><TargetEntity id="D010003" type="MeSH"/><TargetEntity id="-478836143" type="omicsDisease"/><TargetEntity id="747" type="siCondition"/></SourceEntity><SourceEntity id="28" type="ciIndication"><TargetEntity id="10003246" type="MEDDRA"/><TargetEntity id="D001168" type="MeSH"/><TargetEntity id="-1504014133" type="omicsDisease"/><TargetEntity id="720" type="siCondition"/></SourceEntity><SourceEntity id="1001" type="Action"><TargetEntity id="5042" type="Mechanism">Anti-Prostaglandin G/H Synthase 2 (PTGS2; COX-2)</TargetEntity><TargetEntity id="407" type="Mechanism">Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00537" type="ciTarget"><TargetEntity id="208383496557433" type="siTarget">Prostaglandin G/H synthase 2</TargetEntity><TargetEntity id="153" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Osteoarthritis - US - Feb-2016</FirstLaunched><FirstLaunched>Pain - US - Feb-2016</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="20">Pain</Indication><Indication id="245">Osteoarthritis</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="28">Arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="1001">Cyclooxygenase 2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="329">Prostaglandin synthesis inhibitor</Action><Action id="2955">Non-steroidal anti-inflammatory</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="591">Nanoparticle formulation oral</Technology><Technology id="585">Oral formulation</Technology><Technology id="586">Capsule formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-11-02T16:23:49.000Z</LastModificationDate><ChangeDateLast>2018-11-05T00:00:00.000Z</ChangeDateLast><AddedDate>2011-05-03T15:06:12.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1021736" linkType="Company"&gt;iCeutica&lt;/ulink&gt;, a subsidiary of &lt;ulink linkID="1031963" linkType="Company"&gt;Iroko Pharmaceuticals&lt;/ulink&gt;, has developed and launched Vivlodex (IP-045), a once daily nanoformulated version of the NSAID &lt;ulink linkID="3610" linkType="Drug"&gt;meloxicam&lt;/ulink&gt;, using its SoluMatrix platform, for the  treatment of arthritis [&lt;ulink linkID="1188093" linkType="Reference"&gt;1188093&lt;/ulink&gt;], [&lt;ulink linkID="1187094" linkType="Reference"&gt;1187094&lt;/ulink&gt;], [&lt;ulink linkID="1287847" linkType="Reference"&gt;1287847&lt;/ulink&gt;], [&lt;ulink linkID="1706063" linkType="Reference"&gt;1706063&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In February 2016, the drug was launched in the US [&lt;ulink linkID="1735096" linkType="Reference"&gt;1735096&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2018, &lt;ulink linkID="30734" linkType="Company"&gt;Egalet&lt;/ulink&gt; planned to acquire Vivlodex from Iroko. The transaction was expected to close in 1Q19, subject to the reorganization of Egalet under Chapter 11 of the US bankruptcy code [&lt;ulink linkID="2088651" linkType="Reference"&gt;2088651&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2015, an NDA filing for osteoarthritis pain  was accepted by the FDA [&lt;ulink linkID="1641310" linkType="Reference"&gt;1641310&lt;/ulink&gt;].  In October 2015, the drug was approved [&lt;ulink linkID="1706063" linkType="Reference"&gt;1706063&lt;/ulink&gt;]. In February 2016, the drug was launched in the US [&lt;ulink linkID="1735096" linkType="Reference"&gt;1735096&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In  April 2016, pooled data from two phase III studies were presented at the 2016 OARSI World Congress on Osteoarthritis in Amsterdam, the Netherlands.  Selected adverse events, including gastrointestinal disorders, cardiovascular disorders, hepatic disorders, renal disorders were reported [&lt;ulink linkID="1758062" linkType="Reference"&gt;1758062&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, a multicenter, open-label, single-group, safety phase III study (&lt;ulink linkID="113368" linkType="Protocol"&gt;NCT01801735&lt;/ulink&gt;; MEL3-12-03) of the drug in subjects (expected n = 600) with osteoarthritis of the knee or hip was planned to be initiated in March 2013 in the US. At that time, the trial was expected to be completed in July 2014. In August 2014, the trial was completed [&lt;ulink linkID="1388626" linkType="Reference"&gt;1388626&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, a multicenter, randomized, double-blind, double-dummy, placebo-controlled, fixed-dose, parallel-group, efficacy and safety phase III study (&lt;ulink linkID="108933" linkType="Protocol"&gt;NCT01787188&lt;/ulink&gt;; MEL3-12-02) of the drug in patients (expected n = 402) with osteoarthritis pain of the knee or hip was planned to be initiated in the US. At that time, the trial was expected to complete in November 2013; in March 2013, the trial was initiated in patients (n = 403); the study was completed in  November 2013 [&lt;ulink linkID="1382621" linkType="Reference"&gt;1382621&lt;/ulink&gt;]. In June 2014, clinical data were presented at  EULAR 2014 Annual Meeting in Paris, France​. At week 12, treatment with SoluMatrix meloxicam resulted in significant reduction of Western Ontario and McMaster universities osteoarthritis index (WOMAC) pain subscale scores, including WOMAC stiffness subscale and WOMAC function from baseline when compared with placebo.  Significantly greater proportion of patients treated with SoluMatrix meloxicam met the modified OMERACT-OARSI criteria for clinical response at week 12 [&lt;ulink linkID="1564719" linkType="Reference"&gt;1564719&lt;/ulink&gt;]. By October 2015, data demonstrated that VIVLODEX doses  achieved efficacy at 33% lower doses than currently available meloxicam products [&lt;ulink linkID="1706063" linkType="Reference"&gt;1706063&lt;/ulink&gt;]. In May 2016, further data were reported. Data showed that  patients treated with VIVLODEX (meloxicam) capsules consistently used less rescue pain medication, regardless of time of day, compared to patients receiving  placebo. Patients  in the 10 mg (48.4) and 5 mg (52.4) groups received significantly fewer doses of rescue medication over 12-weeks than those in the placebo group (73.2).The mean daily rescue medication dosage was significantly lower in the 10 mg group (313.6) and 5 mg (326.2) group compared to placebo (464.1).The mean number of days with a rescue event was significantly less in the 10 mg group (23.5) and 5 mg (25.3) group compared to placebo (33.9). A dose-related trend was observed in the average number of rescue events per patient over 12-weeks by time of day [&lt;ulink linkID="1761607" linkType="Reference"&gt;1761607&lt;/ulink&gt;]. In May 2016, similar data were presented at the 35th APS Annual Scientific Meeting in Austin, TX [&lt;ulink linkID="1800853" linkType="Reference"&gt;1800853&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, a phase II study was expected to begin in early 2011  [&lt;ulink linkID="1188093" linkType="Reference"&gt;1188093&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2011, a phase I study had been completed and demonstrated that significant levels of meloxicam were achieved within 1 h [&lt;ulink linkID="1188093" linkType="Reference"&gt;1188093&lt;/ulink&gt;]; in May 2012, the drug was still listed as being in phase I development  [&lt;ulink linkID="1287847" linkType="Reference"&gt;1287847&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In  June 2014,  data from a  four-period, four-sequence crossover study were presented at EULAR 2014 Annual Meeting in Paris, France. Lower-dose submicron meloxicam (10 mg) showed similar mean peak plasma meloxicam levels when compared with conventional meloxicam.  Treatment with either lower-dose or conventional dose showed similar drug clearance based on half-life and the terminal elimination rate constant [&lt;ulink linkID="1566564" linkType="Reference"&gt;1566564&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate><Source id="1735096" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate><Source id="1735096" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>2011-05-03T00:00:00.000Z</StatusDate><Source id="1188093" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2013-03-04T00:00:00.000Z</StatusDate><Source id="1382621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2013-03-04T00:00:00.000Z</StatusDate><Source id="1382621" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2015-03-12T00:00:00.000Z</StatusDate><Source id="1641310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2015-03-12T00:00:00.000Z</StatusDate><Source id="1641310" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2015-10-23T00:00:00.000Z</StatusDate><Source id="1706063" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1021736">iCeutica Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="245">Osteoarthritis</Indication><StatusDate>2015-10-23T00:00:00.000Z</StatusDate><Source id="1706063" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00537"><Name>Cyclooxygenase 2</Name><SwissprotNumbers><Swissprot>O02768</Swissprot><Swissprot>O19183</Swissprot><Swissprot>O62698</Swissprot><Swissprot>O62725</Swissprot><Swissprot>P27607</Swissprot><Swissprot>P35354</Swissprot><Swissprot>P35355</Swissprot><Swissprot>P70682</Swissprot><Swissprot>P79208</Swissprot><Swissprot>Q05769</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2088651" linkType="reference" linkID="2088651"&gt;2088651&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031963">Iroko Pharmaceuticals LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30734">Zyla Life Sciences</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1cnc(s1)NC(=O)C2=C(c3ccccc3S(=O)(=O)N2C)O</Smiles></StructureSmiles><Deals><Deal id="250896" title="Egalet acquires Iroko Pharmaceuticals' Vivlodex, Tivorbex, Zorvolex, Indocin and naproxen for pain"/></Deals><PatentFamilies><PatentFamily id="1551541" number="WO-2010121323" title="Method for the production of commercial nanoparticle and microparticle powders"/><PatentFamily id="2069455" number="WO-2010121321" title="Method for improving the dissolution profile of a biologically active material"/><PatentFamily id="2291412" number="WO-2010121320" title="Production of encapsulated nanoparticles at high volume fractions"/><PatentFamily id="2291413" number="WO-2010121322" title="Production of encapsulated nanoparticles at commercial scale"/><PatentFamily id="3084095" number="WO-2015191595" title="Novel formulation of meloxicam"/><PatentFamily id="367319" number="WO-2010121325" title="A novel formulation of meloxicam"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Iroko Pharmaceuticals LLC" id="1031963"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>